AbbVie Analyst Price Targets - Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD82,564.26+0.00%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

AbbVie Inc

ABBVNYSE

Trade with Public

Trade with Public

$276.45

4.031.48%

Last update: Oct 9, 5:40 PM

$276.43

4.011.47%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

AbbVie Analyst Price Targets - Benzinga

AbbVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbbVie (ABBV).

Price Target Range — 8 Quarters

Analyst Consensus — 25 Analysts

21Buy

4Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$271Upside to Avg. PT-2.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	UBS	Michael Yee	PT Raise	Neutral	$260→$275
Oct 9, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$288
Oct 8, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$285→$300
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$285→$290
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$296→$310
Oct 6, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$280→$320
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$300→$315
Aug 20, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$298→$303
Aug 17, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$295→$300
Aug 13, 2026	Wolfe Research	Alexandria Hammond	Upgrade	Peer Perform→Outperform	$300
Aug 11, 2026	BNP Paribas	Navann Ty	PT Raise	Neutral	$218→$247
Aug 10, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$246→$260
Aug 6, 2026	Berenberg	Luisa Hector	Maintained	Buy	$275
Aug 5, 2026	Erste Group	Hans Engel	Upgrade	Hold→Buy	—
Aug 4, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$261→$288
Aug 3, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$278→$296
Aug 3, 2026	Canaccord Genuity	Gary Nachman	PT Raise	Buy	$282→$290
Aug 3, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$265→$285
Jul 31, 2026	TD Cowen	Steve Scala	Maintained	Buy	$280
Jul 31, 2026	William Blair	Matt Phipps	Maintained	Buy	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on AbbVie, Raises Price Target to $275

UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $260 to $275.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

Guggenheim analyst Vamil Divan reiterates AbbVie (NYSE:ABBV) with a Buy and maintains $288 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $300.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $290.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $310

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $296 to $310.

Benzinga Newsdesk

PRO
Scotiabank Maintains Sector Outperform on AbbVie, Raises Price Target to $320

Scotiabank analyst Louise Chen maintains AbbVie (NYSE:ABBV) with a Sector Outperform and raises the price target from $280 to $320.

Benzinga Newsdesk